Jasper Therapeutics Inc SEC Filings

Welcome to our dedicated page for Jasper Therapeutics SEC filings (Ticker: JSPR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

The Jasper Therapeutics, Inc. (JSPR) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a Nasdaq-listed clinical-stage biotechnology issuer. Jasper files reports and current updates with the U.S. Securities and Exchange Commission in connection with its development of briquilimab, an aglycosylated monoclonal antibody targeting KIT (CD117) for chronic mast cell diseases such as chronic urticaria and asthma.

Current Reports on Form 8-K featured here include items on quarterly financial results and corporate updates, public offerings of common stock, pre-funded warrants and common warrants, and material corporate actions such as workforce reductions and operating plan changes. These filings describe how Jasper intends to use offering proceeds to advance preclinical and clinical development of briquilimab in mast cell driven diseases and to fund general corporate purposes.

Filings also disclose Nasdaq listing details for Jasper’s voting common stock (trading symbol JSPR) and redeemable warrants (trading symbol JSPRW), as well as information on shareholder meetings, director elections, advisory votes on executive compensation and the appointment of the independent registered public accounting firm. Selected 8-Ks incorporate press releases that summarize clinical data from the BEACON study in chronic spontaneous urticaria, the ETESIAN study in allergic asthma and related open-label extension work, along with safety and efficacy observations.

On Stock Titan, these SEC documents are paired with AI-powered tools that help readers quickly identify key sections, such as financing terms, use of proceeds, study-related disclosures and governance decisions. Users can review Jasper’s historical and recent filings to understand the company’s reporting history, capital structure developments and the regulatory context for its briquilimab clinical programs.